RxDoctor Payments Data

John Sallach, MD

Cardiovascular Disease · Rochester Hills, MINPI 1457437469

Payments from drug & device makers

$1,013in general payments, 2019–2025

Across 49 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$436
  • Amgen$139
  • Sanofi$125
  • Boston Scientific$75
  • Sanofi-aventis U.S. LLC$73
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$50
  • plus $115 from 6 others

What the payments were for

  • Speaking & faculty fees$12512%
  • Food & beverage$87486%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,013 in reported general payments places this provider in the 30th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$268,098
Medicare patients
1,417
Services billed
2,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$409,600
XareltoRivaroxaban123$169,378
Repatha SureclickEvolocumab99$103,103
EntrestoSacubitril/Valsartan29$51,289
Praluent PenAlirocumab12$15,340
VascepaIcosapent Ethyl17$13,461
Metoprolol Succinate699$12,513
Atorvastatin Calcium496$7,474
Ranolazine ErRanolazine23$3,295
Rosuvastatin Calcium171$2,577
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$2,428
Ezetimibe102$2,211
Losartan Potassium169$2,138
Amlodipine Besylate244$1,611
Carvedilol104$1,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$409,600314 claims
Johnson & JohnsonXarelto$12$169,378123 claims
NovartisEntresto$436$51,28929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →